Efficacy of a simethicone, activated charcoal and magnesium oxide combination (Carbosymag®) in functional dyspepsia: Results of a general practice-based randomized trial

Coffin, Benoït; Bortolloti, Claude; Bourgeois, Odile; Denicourt, Luc

doi:10.1016/j.clinre.2011.02.009

Cited by 16 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those silicone oils, alone or in combination with other drugs, have been evaluated as efficient and well-tolerated agents for versatile gastrointestinal indications. For instance in the treatment of acute diarrhoea [1] , [2] , premedication for upper endoscopy [3] and anorectal ultrasonography [4] , functional dyspepsia [5] , [6] and reflux oesophagitis [7] , [8] . As dimethicone and simethicone bare antifoaming properties [9] , [10] , [11] , they are supposed to disintegrate excess gastrointestinal gas, thus relieving flatulence and abdominal discomfort.…”

Section: Introductionmentioning

confidence: 99%

Thiolated silicone oil: Synthesis, gelling and mucoadhesive properties

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Thiolated silicone oil: Synthesis, gelling and mucoadhesive properties

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Therefore, foam reduction can increase gastric emptying time and relieve postprandial fullness [8][9][10][11][12][13] . Many studies have found that simethicone has efficacy for treatment of dyspepsia and no serious adverse reaction [14][15][16][17] .…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial

2019

View full text Add to dashboard Cite

Background: Proton pump inhibitors are effective for functional dyspepsia but ineffective in relieving postprandial distress syndrome. Curcuma longa might be effective for postprandial distress syndrome. The objective of this study was to compare the efficacy of Curcuma longa and simethicone for postprandial distress syndrome in an open-label randomized-controlled trial. Methods: This trial was conducted between July 2018 and February 2019. In total, 78 patients were randomly assigned to receive 4 weeks of treatment with 750 or 1,500 mg oral Curcuma longa per day or 240 mg simethicone per day. The patients assessed their symptoms using the dyspepsia Global Overall Symptom scale at baseline, week 2, and week 4. After stopping medication for 2 weeks, the patients assessed recurrent symptoms and day of recurrence by themselves at the end of week 6. Results: In total, 78 patients underwent randomization (27 in 750 mg Curcuma longa, 26 in 1500 mg Curcuma longa, and 25 in simethicone groups). After 2 weeks, there were no significant differences in all mean changes of symptoms scores (95%CI) of postprandial distress syndrome [-4.1 (-4.5, -2.6) vs -4.3 (-5.2, -3.3) vs -4.2 (-4.8, -3.5), P=0.954]. Over a period of 4 weeks, the reduction in mean scores was greater among participants receiving simethicone (although not statistically significant) compared with two intervention groups [-4.6 (-5.7, -3.6) vs -5.4 (-6.6, -4.1) vs -6.2 (-7.2, -5.2), P=0.122]. The rate of recurrence was significantly lower in simethicone than the two Curcuma longa groups (42.9 vs 45.5 vs 13.6%, P=0.047). There was no serious adverse event reported in all three groups. Conclusions: Curcuma longa had a similar effect on treatment outcomes to simethicone after 2 and 4 weeks, but the recurrence rate of symptoms was significantly higher without serious adverse events. Registration: Registered with the Thai Clinical Trials Registry on 31 January 2018; TCTR20180131001.

show abstract

“…The literature search yielded 1818 citations, of which 1651 were excluded because they were not clinical trials or written in English. Of the 167 therapeutic trials, 109 did not match the inclusion criteria, leaving 58 studies for the present review . During the time period examined, most of the studies adopted the Rome II criteria (59%), whereas Rome I and Rome III were selected for inclusion criteria in 10% and 31% of the clinical trials respectively.…”

Section: Resultsmentioning

confidence: 99%